Table 1.

Baseline characteristics of study participants according to treatment group

CharacteristicCalcitriol, n=64Cholecalciferol, n=64
Age, yr59±1258±13
Men, N (%)41 (64)45 (70)
Race/ethnicity, N (%)
 Non-Hispanic white23 (36)23 (36)
 Non-Hispanic black14 (22)18 (28)
 Hispanic23 (36)16 (25)
 Other4 (6)7 (11)
Diabetes, N (%)32 (50)26 (41)
Hypertension, N (%)61 (95)62 (97)
Coronary artery disease, N (%)10 (16)11 (17)
Smoking status, N (%)
 Never36 (56)33 (52)
 Former5 (8)14 (22)
 Current21 (33)17 (27)
Etiology of kidney disease, N (%)
 Diabetes31 (48)24 (38)
 Hypertension15 (23)17 (27)
 PKD1 (2)4 (6)
 GN9 (14)6 (9)
 Obstruction3 (5)2 (3)
 Unknown13 (20)8 (13)
Medication use, N (%)
 ACE-I/ARB42 (66)43 (67)
 Diuretics44 (69)40 (63)
 Lipid-lowering agents34 (53)36 (56)
Body mass index, kg/m232.0±5.530.4±5.4
eGFR, ml/min per 1.73 m232.8±10.033.5±10.4
Systolic BP, mmHg132±18132±17
Calcium, mg/dl9.0±0.49.1±0.4
Phosphorus, mg/dl3.6±0.63.7±1.0
25(OH)2D, ng/ml21.7±7.723.0±7.6
1,25(OH)2D, pg/ml29.4±11.229.2±11.1
PTH, pg/ml, median [IQR]93.8 [60.7–139.4]99.5 [62.2–145.7]
FGF23, pg/ml, median [IQR]86.0 [56.3–118.2]89.0 [60.3–131.8]
C-reactive protein, mg/dl, median [IQR]3.4 [1.5–6.7]3.0 [1.2–7.9]
IL-6, mg/dl, median [IQR]3.0 [1.8–4.2]3.5 [1.8–4.7]
Urinary albumin-to-creatinine ratio, mg/g, median [IQR]222.0 [39.7–846.8]158.8 [29.2–585.6]
  • All values are expressed as means±SD unless otherwise specified. PKD, polycystic kidney disease; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; PTH, parathyroid hormone; IQR, interquartile range; FGF23, fibroblast growth factor 23.